Bradford C Dickerson is an expert in Neurology at Massachusetts General Hospital (United States). As of October 2026, ScienceLeadR ranks Bradford C Dickerson in the top 1% of experts worldwide for Dementia, Neurocognitive Disorders and Language Disorders. Bradford C Dickerson has authored 688 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 2 of them ongoing. SLR score: 3,237 (community average: 125). How the SLR is computed.

LeadR Profile

Bradford C Dickerson Massachusetts General Hospital United States
3 237 ScienceLeadR Reputation 3237
Network Map

Neurology

Subspecialties: Psychiatry - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1999 - 2026

Source: PubMed

Massachusetts General Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 688

Citations

Citations: 51 749 1st author: 42 Last author: 139 Unique author: 20


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Hemispheric Asymmetry of Neuroimaging Biomarkers in Early Onset Alzheimer's Disease: Clinical and Cognitive Outcomes.
PMID 42873606 — atrophy, neuroimaging, alzheimer disease, phenotype, biomarkers, amyloid
Ann Neurol20260
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.
PMID 42441390 — alzheimer disease, positron-emission tomography, diagnosis, amyloid
JAMA Top journal20267
Neural and Behavioral Predictors of Speech Motor Sequence Learning in Primary Progressive Aphasia.
PMID 42798738 — aphasia, primary progressive, aphasia, learning, speech
Neurobiol Lang (Camb)20260
Enhancing brain age estimation with structural MRI and synthesized cerebral blood volume maps.
PMID 42683072 — blood, atrophy, brain, magnetic resonance imaging, cognitive dysfunction, biomarkers, blood volume, deep learning, cognition disorders, cerebral blood volume, learning, mental status and dementia tests
Brain Commun20260
EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker.
PMID 42647766 — dementia, atrophy, alzheimer disease, cognitive dysfunction, biomarkers, neurology
Neurology20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 7
Phase 3 1

By status:

Completed 4
Active not recruiting 2
Recruiting 2

By type:

Interventional 7
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 0
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 15

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Resilient Together for Dementia
NCT06421545 — dementia, alzheimer disease, diagnosis, psychological distress
N/ARecruiting2024
Tau PET CT Imaging in the Mismatch Prospective Cohort Study (MPC TAU)
NCT05658913 — cross-sectional studies, alzheimer disease, pathology, cohort studies, cognitive dysfunction, positron emission tomography computed tomography, biomarkers, carbolines
N/ARecruiting2023

LeadR Networks

Main global connection map